Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.01 USD | -1.47% | -12.61% | -58.81% |
Financials (USD)
Sales 2024 * | 105M | Sales 2025 * | 129M | Capitalization | 99.27M |
---|---|---|---|---|---|
Net income 2024 * | -51M | Net income 2025 * | -32M | EV / Sales 2024 * | 1.11 x |
Net Debt 2024 * | 16.38M | Net Debt 2025 * | 13.37M | EV / Sales 2025 * | 0.87 x |
P/E ratio 2024 * |
-1.85
x | P/E ratio 2025 * |
-3.33
x | Employees | 330 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 52.84% |
Latest transcript on Akoya Biosciences, Inc.
1 day | -1.47% | ||
1 week | -12.61% | ||
Current month | -6.51% | ||
1 month | -50.25% | ||
3 months | -66.39% | ||
6 months | -58.47% | ||
Current year | -58.81% |
Managers | Title | Age | Since |
---|---|---|---|
Brian McKelligon
CEO | Chief Executive Officer | 55 | 17-06-30 |
Johnny Ek
DFI | Director of Finance/CFO | 49 | 23-03-19 |
Pascal Bamford
CTO | Chief Tech/Sci/R&D Officer | - | 21-10-25 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Shepler
CHM | Chairman | 67 | 15-10-31 |
Myla Lai-Goldman
BRD | Director/Board Member | 66 | 21-09-15 |
Director/Board Member | 67 | 19-08-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 0 M€ | 0.00% | - | |
0.02% | 0 M€ | 0.00% | - | |
0.00% | 1,487 M€ | +7.26% | - | |
0.00% | 9 M€ | +8.96% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-04 | 2.01 | -1.47% | 192,407 |
24-06-03 | 2.04 | -5.12% | 246,681 |
24-05-31 | 2.15 | +1.90% | 198,857 |
24-05-30 | 2.11 | -6.64% | 247,788 |
24-05-29 | 2.26 | -1.74% | 653,048 |
Delayed Quote Nasdaq, June 04, 2024 at 03:59 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-58.81% | 101M | |
+7.32% | 217B | |
+13.83% | 194B | |
+20.48% | 143B | |
+31.33% | 111B | |
+3.08% | 64.3B | |
+14.64% | 52.94B | |
+2.72% | 49.53B | |
-5.88% | 38.31B | |
+0.25% | 35.22B |
- Stock Market
- Equities
- AKYA Stock